Count Citron Research is a believer in tobacco and cannabis company Pyxus International Inc. (PYX - Get Report) , following a bullish research note on the company Monday, October 8. 

Citron believes that the North Carolina-based company could double from its opening position Monday, as long as investors are still pot crazy. 

$PYX would not short...speculative long. Real management and tight float. The stock could double from here as long as investors are Cannabis crazy. Our favorite hire..and it wasn't last week.

— Citron Research (@CitronResearch) October 8, 2018

Pyxus supplies tobacco leaves to cigarette manufacturers, but, since it announced on October 2 that its indirect subsidiary Goldleaf Pharm received a medical cannabis cultivation license in Canada the company has been swept up in the cannabis craze. 

Shares of Pyxus closed trading up 36.6% to $38.52 Monday. 

Meanwhile, fellow cannabis plays Tilray Inc. (TLRY) and DAVIDsTea Inc. (DTEA - Get Report) are down 4.7% and 5.2%, respectively.